Skip to main content
. 2017 Feb 9;8(10):16951–16963. doi: 10.18632/oncotarget.15208

Figure 2. ELF3 is a favorable prognostic marker for ovarian carcinoma.

Figure 2

(A) Kaplan-Meier analysis of 112 study patients with advanced ovarian carcinoma showing a significant correlation between ELF3 protein expression and overall survival with use of the mean ELF3 staining intensity as the cutoff (log-rank test; p < 0.001). Correlation of ELF3 protein expression with survival was maintained after stratification according to age and debulking status. (B) Kaplan-Meier analysis of a TCGA ovarian cancer data set consisted of 385 patients with advanced ovarian carcinoma. The ELF3 mRNA expression z-scores for the 385 tumor samples were calculated. A z-score of –2 was used as a cutoff to classify the samples into high and low ELF3 expression groups. The red line represents samples with z-scores for ELF3 expression less than –2, and the blue line represents samples with z-scores of –2 to 2. Kaplan-Meier survival analysis for the two groups of patients was performed using the cBioPortal for Cancer Genomics. The patients with low ELF3 expression (z-score < –2) had a median survival duration of 34 months (n = 15), and the patients with high ELF3 expression (–2 < z-score < 2) had a median survival duration of 45.5 months (n = 299).